Sirona Biochem Announces 2022 Annual Meeting Results
30 Diciembre 2022 - 12:22PM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) announces the voting results from its
Annual General Meeting of Shareholders (the "Meeting"), held in
Vancouver, British Columbia on December 30, 2022. The total number
of shares represented by shareholders present in person and by
proxy at the Meeting was 23,664,112, representing 9.39% of Sirona's
issued and outstanding Common Shares.
All matters put forward to shareholders for
consideration and approval, as set out in the Company's Management
Information Circular dated 30th of November, 2022, were approved by
the requisite majority of votes cast at the Meeting. These
were:
1. To elect Sirona’s board of directors; 2. to
fix the number of directors of the Company at five; 3. to appoint
DeVisser Gray LLP, Chartered Professional Accountants, as the
Company’s auditor for the ensuing year and authorize the directors
to set the auditor’s remuneration; and 4. to confirm and approve
the Company’s existing stock option plan.
Sirona would like to thank all shareholders for
their continued support.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
---------------------------------------------
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise.
Actual results, performance or achievement could differ materially
from those expressed in, or implied by, Sirona Biochem’s
forward-looking statements due to the risks and uncertainties
inherent in Sirona Biochem’s business including, without
limitation, statements about: the progress and timing of its
clinical trials; difficulties or delays in development, testing,
obtaining regulatory approval, producing and marketing its
products; unexpected adverse side effects or inadequate therapeutic
efficacy of its products that could delay or prevent product
development or commercialization; the scope and validity of patent
protection for its products; competition from other pharmaceutical
or biotechnology companies; and its ability to obtain additional
financing to support its operations. Sirona Biochem does not assume
any obligation to update any forward-looking statements except as
required by law.
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024